Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. is a biotechnology company that engages in the development of a new class of cancer treatments, utilizing its proprietary Gene Traffic Control platform. The primary aim of the company is to decode the regulatory regions of the genome to discover and develop innovative therapies that target the chromatin regulatory system. Foghorn's focus on chromatin biology enables it to address difficult-to-treat indications by modulating gene expression patterns central to cancer development. Operating primarily within the realm of oncology, Foghorn Therapeutics seeks to bring novel approaches to cancer treatment, impacting areas such as targeted therapies and personalized medicine. The company's efforts are significant in the biotechnology landscape, pushing the boundaries of cancer research by exploring the relationship between gene regulation and disease. Headquartered in Cambridge, Massachusetts, Foghorn continues to advance its pipeline with the hope of delivering new therapeutic options to patients worldwide.